Antibodies with proteolytic activity against MBP have been identified and characterized in detail in a number of autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus (Polosukhina et al., 2004; Bezuglova et al., 2011), as well as in autism (Gonzalez-Gronow et al., 2015), schizophrenia (Parshukova et al., 2020b; Parshukova et al., 2019) and bipolar disorder  (Baranova et al., 2019). This evidence concerns the gene MBP and autoimmune disease.